The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.
Pembrolizumab Promising in Treating Soft Tissue Sarcoma
Caring for Patients Is a Team Sport
Experts Call for Improved Management Strategies for Dedifferentiated Liposarcoma
Zeroing in on Sarcoma Subtypes to Optimize Treatment Outcomes
Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors
Watch the series now!
Dr Mrinal Gounder: Nirogacestat Approval Provides First-in-Class Option for Desmoid Tumor Treatment
Combined Radiotherapy and Surgery Effective for Extremity STS
Treating Sarcomas With Cutting-Edge Immune Checkpoint Blockade
Key MRI Features That Likely Correlate With STS Malignancy Grades
Dr Ravin Ratan on Treating Soft Tissue Sarcomas: Children vs Adults
Experts Advise Caution on Reresections for Low-Grade Sarcomas
Dr Ravin Ratan Breaks Down Classification of Soft Tissue Sarcomas
Improved Survival in Sarcoma Patients: Key Insights on Immunotherapy Sequencing
Margin Status Likely Not a Factor in STS Recurrence
Review: Male Kidney Transplant Recipients More Likely to Develop Kaposi Sarcoma
Anlotinib Enhances Desmoid Fibromatosis Control in New Study
Study Sees Limited Success for Extrapleural Pneumonectomy in Sarcoma Cases
Nirogacestat Linked With Improved Functional Status in Patients With Desmoid Tumors
FDA Approves Nirogacestat for Treatment of Desmoid Tumors